The newly identified miR-483-5p/EGR3 pathway provides further insights into the development and metastasis of NPC and may provide a potential therapeutic target for NPC treatment in order to improve survival of NPC patients. This evidence concerns the gene EGR3 and nasopharyngeal carcinoma.